Revenues Rise at Allos, Awaits Merger - Analyst Blog
August 05 2011 - 10:30AM
Zacks
Allos Therapeutics
Inc.’s (ALTH) second quarter 2011 earnings of $0.02
compared favorably with the loss of $0.19 per share incurred in the
year-ago quarter. A surge in revenues led to the profit in the
second quarter of 2011. The Zacks Consensus Estimate hinted at a
loss of $0.14 per share.
Quarterly
Results
Total revenues in the reported
quarter climbed to $39.1 as opposed to $7.9 million in the year ago
quarter. The massive jump was attributable to the presence of $28.1
million in the reported quarter as license and other revenue
pertaining to the deal signed with Mundipharma International
Corporation Ltd. to co-develop Allos’ sole marketed product
Folotyn. Revenues breezed past the Zacks Consensus Estimate of $12
million.
The agreement with Mundipharma was
signed in May 2011. Per the terms of the deal, the sole
responsibility of commercializing the drug in the US and Canada
lies with Allos. Mundipharma is responsible for commercializing
Folotyn in rest of the world. The deal has strengthened Allos’
balance sheet substantially and the company has already received
$50 million as upfront payment with the potential of receiving
substantial milestone payments.
Allos exited the second quarter of
2011 with $109.5 million in cash, cash equivalents and investments
and no debt as opposed to a cash balance of $79.5 million and zero
debt at the end of the first quarter of 2011.
Folotyn, marketed for treating
patients with relapsed or refractory peripheral T-cell lymphoma
(PTCL), recorded sales of $11.0 million in the reported quarter, up
39.3%.
Operating costs and expenses
(excluding non-cash stock based compensation expense of $2.6
million and cost of license and other revenue of $10.6 million) in
the reported quarter declined 5.9% to $23.6 million. Selling,
general and administrative expenses fell marginally to $20.2
million in the second quarter of 2011 due to lower costs incurred
on selling Folotyn. Research and development expenses fell 21.5% to
$5.1 million.
Allos to Merge with
AMAG
On July 20, 2011, Allos announced
that it will merge with Lexington, Massachusetts based AMAG
Pharmaceuticals (AMAG), a biopharmaceutical company which
focuses on developing and commercializing a therapeutic iron
compound for treating patients suffering from iron deficiency
anemia. Per the terms of the deal, Allos' shareholders will receive
0.128 shares of AMAG per share of Allos.
The all-stock deal, expected to
close by year-end, will involve a one-time cost in the range of $35
million - $38 million. Following the deal, AMAG shareholders will
own approximately 61% of the combined company while Allos
shareholders will own the balance. The deal will bring together
AMAG’s and Allos’ sole marketed products, Feraheme and Folotyn,
respectively.
The merged entity, which will be
headquartered in Lexington, Massachusetts, is expected to generate
annual cost synergies in the range of $55 million - $60 million by
eliminating certain costs, most of which will be realized in the
first year after the merger. The merged entity will also benefit
from a strong balance sheet which will enable it to diversify its
product portfolio and aid business reinvestments.
Forecast for
2011
For 2011, Allos continues to expect
operating costs and expenses (excluding cost of sales, cost of
license and other revenue and non-cash stock-based compensation
expense) in the range of $95 million - $98 million. The projection
does not include the transaction costs that would be incurred upon
and after the closing of the merger.
Stock-based compensation expenses
are expected in the range of $13 million - $14 million for 2011. As
the merger with AMAG is expected to close by year-end, Allos did
not provide any guidance with respect to net product sales for the
second half of 2011.
However, Allos expects license and
other revenue to be approximately $4 million and cost of license
and other revenue to be about $2 million in the latter half of
2011. These projections relate to Allos’ agreement with
Mundipharma.
Our
Recommendation
Currently, we are Neutral on Allos.
The stock carries a Zacks #4 Rank (Sell rating) in the
short-run.
ALLOS THERAPEUT (ALTH): Free Stock Analysis Report
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
Zacks Investment Research
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2023 to Jun 2024